IKT (Inhibikase Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 11, 2025)

Inhibikase Therapeutics Price-to-Free-Cash-Flow Chart

Inhibikase Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Free-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inhibikase Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Inhibikase Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Price-to-Free-Cash-Flow falls into.

Inhibikase Therapeutics Price-to-Free-Cash-Flow Calculation

Inhibikase Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Inhibikase Therapeutics's Share Price of today is $2.00.
Inhibikase Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Inhibikase Therapeutics  (NAS:IKT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Inhibikase Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics Business Description